3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Small Cell Lung Carcinoma
2
Squamous Cell Carcinoma of Head and Neck
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Laryngeal Diseases
1
Head and Neck Neoplasms
1
Interventions
pembrolizumab
27
Cisplatin
18
Cetuximab
12
Carboplatin
12
Surveys and Questionnaires
8
Radiotherapy
8
Paclitaxel
8
Docetaxel
6
Radiotherapy, Intensity-Modulated
5
Surgical Procedures, Operative
4
dostarlimab
3
Therapeutics
3
Standard of Care
3
Fluorouracil
3
Cyclophosphamide
3
Chemoradiotherapy
3
Blood Specimen Collection
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
toripalimab
2
nimotuzumab
2
fludarabine
2
durvalumab
2
atezolizumab
2
abemaciclib
2
X-Rays
2
Taxes
2
Radiosurgery
2
Radiation
2
Nivolumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
monalizumab
×
90 days
×
Clear all
NCT04590963
2026-06-01
INTERLINK-1
AstraZeneca
Phase 3
Active not recruiting
370 enrolled
21 charts